Patients With COVID-19 Infection Who Received Nirmatrelvir-Ritonavir More Likely To Experience Viral Rebound, Study Indicates

Infectious Disease Advisor (1/10, Barowski, RN) reports, “Although nirmatrelvir-ritonavir is associated with fewer COVID-19 symptoms and reduced viral load, it may increase risk for viral rebound,” according to a study. The findings were published in Clinical Infectious Diseases.